A Phase 2 Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; FF 10501 (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors FujiFilm Pharmaceuticals USA
- 24 Jan 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2023.
- 24 Jan 2019 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2022.
- 24 Jan 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.